Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppressor of activator protein-1 regulated by interferon expression in prostate cancer tissues and cells.
|
31276688 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correction to: MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
|
31387585 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we construct a mechanism-based mathematical model that allows us to capture the interactions ofdifferent phosphoforms of PAGE4 with AP-1 and its downstream target, the androgen receptor (AR)-a key therapeutic target in prostate cancer.
|
29758263 |
2018 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
|
28241827 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, to determine the implication of AR and AP-1 in promoting the transition of prostate cancer to the androgen-independent state, we used AR-positive LNCaP and AR-negative PC-3 cells as an in vitro model system.
|
28386843 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, luciferase reporter gene assay showed that the transcriptional activity of AP-1 and NF-κB in PC-3 and LNCaP prostate carcinoma cell lines was also modulated by the overexpression of EGR-1 in these cells using tandem repeated Luc-AP-1 and Luc-NF-κB.
|
21617851 |
2011 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that Egr-1 may promote prostate cancer development by modulating the activity of factors NF-κB and AP-1, which are involved in cell proliferation and apoptosis.
|
21743958 |
2011 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.
|
19787273 |
2009 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells.
|
16964758 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we determined the effects of SFN, PEITC and AITC on AP-1 activation, and investigated the roles of extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways in the regulation of AP-1 activation and cell death elicited by these ITCs in human prostate cancer PC-3 cells.
|
16272172 |
2006 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effects of androgen-activated androgen receptor on AP-1 activity were determined in the LNCaP human prostate carcinoma cell model.
|
15486991 |
2005 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results support the notion that HARP is important for human prostate cancer cell proliferation and migration, establish the role of AP-1 in the up-regulation of HARP expression by low concentrations of HP, and characterize the AP-1 dimers involved.
|
16199533 |
2005 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate for the first time that a combined aberrant activation of NF-kappaB p50 and p65 and AP-1 JunD and Fra-1 in androgen-independent prostate cancer cells results in deregulated IL-6 expression, suggesting a novel potential entry point for therapeutic intervention in prostate cancer.
|
12727841 |
2003 |